Foripharm exceeds annual profit target in first half of 2026

Foripharm (DP3), officially known as Central Pharmaceutical Joint Stock Company 3, has exceeded its full-year profit target within the first six months of 2026. According to its Q2 2026 financial statements, the company reported net revenue of 129 billion VND, a nearly 37% increase compared to the same period last year.

After-tax profit for Q2 2026 reached 39 billion VND, up 22% year-on-year. For the first half of the year, cumulative revenue rose 41% compared to the previous year, while after-tax profit achieved 103% of the annual plan. This growth is attributed to strong market demand and a distribution model that relies heavily on the Over-the-Counter (OTC) channel, which contributes nearly 70% of total revenue.

The company’s product portfolio includes over 100 items, with the ‘Sam nhung bo than TW3’ supplement contributing approximately 30-40% of total revenue. Foripharm operates two GMP-WHO standard factories and maintains a closed business model from production to distribution.